Science updates
26 Aug 2024Navigating FVIII Replacement Pharmacokinetics in Haemophilia A
Although a standardised FVIII replacement product classification could help guide treatment decisions for haemophilia A, the criteria used to define FVIII replacement products continues to vary. In a recent systematic literature review, the clinical and pharmacokinetic (PK) criteria used to define FVIII replacement products in clinical trials, real-world studies, population PK models, case reports/series, reviews and guidelines were summarised.
Click here to hear Mariasanta Napolitano's thoughts on which PK parameters are most clinically relevant in haemophilia A, and how PK properties can vary between FVIII replacement products in real-world studies.
If you would like to read the full publication, please click here.